Curaleaf Holdings (CURLF) Cash from Financing Activities (2019 - 2024)
Curaleaf Holdings (CURLF) posted quarterly Cash from Financing Activities of -$6.6 million for Q4 2024, up 61.27% year-over-year from -$4.1 million in Q1 2024, and up 46.11% quarter-over-quarter from -$12.2 million in Q3 2024.
Curaleaf Holdings (CURLF) Cash from Financing Activities (2019 - 2024) Analysis & Trends
Curaleaf Holdings' Cash from Financing Activities history runs 6 years deep, the most recent figure standing at -$6.6 million for Q4 2024.
- In Q4 2024, Cash from Financing Activities rose 61.27% year-over-year to -$6.6 million; the TTM figure through Dec 2024 stood at -$54.1 million (up 19.26% YoY), while the FY2025 annual figure was -$73.5 million, down 35.86% from the prior year.
- Cash from Financing Activities for Q4 2024 stood at -$6.6 million, up from -$12.2 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $28.6 billion in Q2 2023, with the low at -$28.6 billion in Q1 2023.
- The 5-year median for Cash from Financing Activities is $1.7 million (2020), against an average of $27.4 million.
- Peak annual rise in Cash from Financing Activities reached 59634.52% in 2023, while the deepest fall reached 171254.23% in 2023.
- Curaleaf Holdings' Cash from Financing Activities stood at $3.4 million in 2020, then soared by 2674.62% to $95.2 million in 2021, then slumped by 59.54% to $38.5 million in 2022, then plunged by 144.09% to -$17.0 million in 2023, then surged by 61.27% to -$6.6 million in 2024.
- Business Quant data shows CURLF's Cash from Financing Activities at -$6.6 million in Q4 2024, -$12.2 million in Q3 2024, and -$15.7 billion in Q2 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Curaleaf Holdings | 2.61 Bn | 2.52 Bn | 169.91 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -6.58 Mn |
| Dec 31, 2024 | -6.58 Mn |
| Sep 30, 2024 | -12.21 Mn |
| Sep 30, 2024 | -12.21 Mn |
| Jun 30, 2024 | -15.73 Bn |
| Jun 30, 2024 | -15.73 Bn |
| Mar 31, 2024 | 15.70 Bn |
| Mar 31, 2024 | 15.70 Bn |
| Dec 31, 2023 | -16.99 Mn |
| Dec 31, 2023 | -16.99 Mn |
| Sep 30, 2023 | 5.06 Mn |
| Sep 30, 2023 | 5.06 Mn |
| Jun 30, 2023 | 28.59 Bn |
| Jun 30, 2023 | 28.59 Bn |
| Mar 31, 2023 | -28.65 Bn |
| Mar 31, 2023 | -28.65 Bn |
| Dec 31, 2022 | 38.53 Mn |
| Dec 31, 2022 | 38.53 Mn |
| Sep 30, 2022 | -27.89 Mn |
| Sep 30, 2022 | -27.89 Mn |